Shares of Cellebrite DI Ltd. (NASDAQ:CLBT – Get Rating) have earned a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.71.
CLBT has been the topic of a number of analyst reports. Cowen lowered their price objective on Cellebrite DI from $13.00 to $10.00 and set an "outperform" rating on the stock in a report on Friday, August 12th. Bank of America downgraded Cellebrite DI from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $6.50 to $6.00 in a research report on Friday, August 12th. Cowen cut their price target on Cellebrite DI from $13.00 to $10.00 and set an "outperform" rating for the company in a report on Friday, August 12th. William Blair downgraded Cellebrite DI from an "outperform" rating to a "market perform" rating in a report on Friday, August 12th. Finally, Needham & Company LLC boosted their price objective on shares of Cellebrite DI from $6.00 to $6.50 and gave the company a "buy" rating in a research note on Thursday, August 11th.
Get
Cellebrite DI alerts:
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the stock. ARK Investment Management LLC bought a new stake in Cellebrite DI during the first quarter worth approximately $2,621,000. Mawer Investment Management Ltd. raised its holdings in shares of Cellebrite DI by 144.1% during the 1st quarter. Mawer Investment Management Ltd. now owns 208,747 shares of the company's stock valued at $1,336,000 after purchasing an additional 123,232 shares in the last quarter. Greenhaven Road Investment Management L.P. raised its holdings in shares of Cellebrite DI by 69.7% during the 1st quarter. Greenhaven Road Investment Management L.P. now owns 2,000,000 shares of the company's stock valued at $12,800,000 after purchasing an additional 821,364 shares in the last quarter. Josh Arnold Investment Consultant LLC acquired a new position in Cellebrite DI in the 1st quarter valued at $64,000. Finally, CIBC Asset Management Inc grew its stake in Cellebrite DI by 5.8% in the 1st quarter. CIBC Asset Management Inc now owns 2,352,733 shares of the company's stock valued at $15,057,000 after buying an additional 129,244 shares during the last quarter. 20.41% of the stock is currently owned by institutional investors.
Cellebrite DI Stock Performance
CLBT opened at $4.05 on Wednesday. Cellebrite DI has a one year low of $3.98 and a one year high of $11.40. The business's 50-day simple moving average is $4.98 and its 200-day simple moving average is $5.30. The stock has a market capitalization of $768.08 million, a P/E ratio of 5.47, a price-to-earnings-growth ratio of 10.18 and a beta of 0.87.
Cellebrite DI Company Profile
(Get Rating)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation.
Recommended Stories
- Get a free copy of the StockNews.com research report on Cellebrite DI (CLBT)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
